Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial - The Lancet Diabetes & Endocrinology

Proposal for Standardization of Primary and Secondary Outcomes in

Sherita Hill Golden: tackling the source of health disparities

PDF) Traditional Chinese medicine in thyroid-associated orbitopathy

Effect of dapagliflozin on the rate of decline in kidney function

Full article: How can we prevent disease relapse in Graves

View of Cardiovascular outcomes trials with statins in diabetes

Effect of dapagliflozin on the rate of decline in kidney function

Adverse events associated with unblinded, but not with blinded

Statins for Graves' orbitopathy (STAGO): a phase 2, open-label

Rosuvastatin in the Primary Prevention of Cardiovascular Disease

Frontiers Effects of Non-statin Lipid-Modifying Agents on

Efficacy and safety of osilodrostat in patients with Cushing's

Statins and Risk of New-Onset Diabetes Mellitus

Statin use associated with lower incidence of developing thyroid